MedTrace Logo

A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS

NCT05053035 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2025-06-18

Study results available
· View outcomes & findings →

Summary

A phase 2 double-blind, placebo-controlled study of AL001 in participants with C9orf72-associated ALS.

Conditions

Interventions

DRUG

AL001

Administered via intravenous (IV) infusion

DRUG

Placebo

Administered via intravenous (IV) infusion

Sponsors & Collaborators

  • Alector Inc.

    lead INDUSTRY

Principal Investigators

  • Sabrina Paganoni, MD · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-02
Primary Completion
2022-10-28
Completion
2022-10-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05053035 on ClinicalTrials.gov